JP2011521654A - Rnaに基づくウイルスベクター系を提供するペスチウイルスレプリコン - Google Patents

Rnaに基づくウイルスベクター系を提供するペスチウイルスレプリコン Download PDF

Info

Publication number
JP2011521654A
JP2011521654A JP2011512010A JP2011512010A JP2011521654A JP 2011521654 A JP2011521654 A JP 2011521654A JP 2011512010 A JP2011512010 A JP 2011512010A JP 2011512010 A JP2011512010 A JP 2011512010A JP 2011521654 A JP2011521654 A JP 2011521654A
Authority
JP
Japan
Prior art keywords
replicon
gene
pro
protein
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011512010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521654A5 (enExample
Inventor
ヨン ドゥリ トラッティン
ニコラス ルグリ
ケネス チャールズ マッカルー
Original Assignee
インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ filed Critical インスティトゥート フュア ヴィルスクランクハイテン ウント イムンプロフィラクセ
Publication of JP2011521654A publication Critical patent/JP2011521654A/ja
Publication of JP2011521654A5 publication Critical patent/JP2011521654A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24342—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24341—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011512010A 2008-06-04 2009-05-30 Rnaに基づくウイルスベクター系を提供するペスチウイルスレプリコン Pending JP2011521654A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08010222A EP2130912A1 (en) 2008-06-04 2008-06-04 Pestivirus replicons providing an RNA-based viral vector system
EP08010222.1 2008-06-04
PCT/EP2009/003892 WO2009146867A1 (en) 2008-06-04 2009-05-30 Pestivirus replicons providing an rna-based viral vector system

Publications (2)

Publication Number Publication Date
JP2011521654A true JP2011521654A (ja) 2011-07-28
JP2011521654A5 JP2011521654A5 (enExample) 2015-08-27

Family

ID=39967852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011512010A Pending JP2011521654A (ja) 2008-06-04 2009-05-30 Rnaに基づくウイルスベクター系を提供するペスチウイルスレプリコン

Country Status (5)

Country Link
US (2) US9249395B2 (enExample)
EP (2) EP2130912A1 (enExample)
JP (1) JP2011521654A (enExample)
CA (1) CA2723999C (enExample)
WO (1) WO2009146867A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
JP5911870B2 (ja) * 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするrnaの送達のためのpeg化リポソーム
EP3542789A3 (en) * 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
KR102266691B1 (ko) 2010-10-11 2021-06-23 노파르티스 아게 항원 전달 플랫폼
RU2014104090A (ru) * 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US10022436B2 (en) 2016-01-11 2018-07-17 Verndari, Inc. Microneedle compositions and methods of using same
EP4166161B1 (en) 2016-04-14 2026-03-04 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
KR102681292B1 (ko) 2016-06-24 2024-07-03 론자 리미티드 가변 직경 생물 반응기
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
WO2018129270A1 (en) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systems and methods to improve vaccine efficacy
WO2019143948A1 (en) 2018-01-18 2019-07-25 Fred Hutchinson Cancer Research Center Altering inflammatory states of immune cells in vivo by modulating cellular activation states
KR102764120B1 (ko) 2019-12-31 2025-02-06 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
KR20230051172A (ko) 2020-07-16 2023-04-17 아퀴타스 테라퓨틱스 인크. 지질 나노 입자에 사용하기 위한 양이온성 지질
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
EP4474015A1 (en) 2023-06-05 2024-12-11 Veterna Srl Noda-like rna-vaccine pharmacon and production and uses thereof
CN118955658A (zh) * 2024-07-26 2024-11-15 华南农业大学 一种重组猪瘟病毒Npro蛋白、抗猪瘟病毒Npro蛋白的多克隆抗体及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053766A1 (en) * 1999-03-08 2000-09-14 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
WO2004092386A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells
JP2005508610A (ja) * 2001-05-23 2005-04-07 インスティティ・パスツール 異種タンパク質の製造に有用なプラス鎖rnaウイルスゲノムに由来するレプリコン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168942B1 (en) * 1998-11-10 2001-01-02 Pfizer Inc. Attenuated forms of bovine viral diarrhea virus
BR0313113A (pt) * 2002-08-13 2005-06-28 Akzo Nobel Nv Replicon de um pestivìrus partìcula viral infecciosa de pestivìrus, método para a produção da mesma, e, vacina
EP1874825B1 (en) * 2005-04-26 2010-03-24 Sandoz AG Affinity ligands
US20080305130A1 (en) * 2005-12-07 2008-12-11 Chichi Huang Marked Bovine Viral Diarrhea Virus Vaccines
EP2130912A1 (en) * 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053766A1 (en) * 1999-03-08 2000-09-14 Stichting Dienst Landbouwkundig Onderzoek Non-spreading pestivirus
JP2005508610A (ja) * 2001-05-23 2005-04-07 インスティティ・パスツール 異種タンパク質の製造に有用なプラス鎖rnaウイルスゲノムに由来するレプリコン
WO2004092386A2 (en) * 2003-04-11 2004-10-28 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Inducing a t cell response with recombinant pestivirus replicons or recombinant pestivirus replicon-transfected dendritic cells

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
JPN6014000534; Journal of Virology Vol.72, 1998, p.7681-7684 *
JPN6014000535; Journal of Virology Vol.72, 1998, p.5318-5322 *
JPN6014000537; Vet.Res. Vol.37, 2006, p.655-670 *
JPN6014052780; Eur. J. Immunol.,1993年,Vol.23,p.1719-1722 *
JPN6014052783; 日本獣医学会学術集会講演要旨集,2005年,Vol.140,p.112,DV-55 *
JPN6014052786; Journal of Virological Methods,1998年,Vol.70,p.93-101 *
JPN6014052787; 日本獣医学会学術集会講演要旨集,2006年,Vol.142,p.86,DV-29 *
JPN6014052789; Journal of Virology,2004年,Vol.78,p.2414-2425 *
JPN6014052791; 日本ウイルス学会第54回学術集会プログラム・抄録集,2006年,p.157,1B01 *

Also Published As

Publication number Publication date
US9670466B2 (en) 2017-06-06
US20110189224A1 (en) 2011-08-04
US9249395B2 (en) 2016-02-02
CA2723999C (en) 2022-03-15
CA2723999A1 (en) 2009-12-10
EP2130912A1 (en) 2009-12-09
US20160108372A1 (en) 2016-04-21
WO2009146867A1 (en) 2009-12-10
EP2297309A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
US9670466B2 (en) Pestivirus replicons providing an RNA-based viral vector system
JP5538729B2 (ja) 偽感染性フラビウイルスおよびそれらの使用
EP0977587B1 (en) Chimeric flavivirus vaccines
US8784839B2 (en) Attenuated live vaccines
KR101158741B1 (ko) HCV의 폴리프로테인 NS3/NS4 및 폴리펩티드NS5b를 포함하는 조성물, 이에 상응하는 뉴클레익서열을 함유하는 발현 벡터, 및 그의 치료적 용도
EP2303320B1 (en) Attenuated pestivirus
US20190111125A1 (en) Bacterial artificial chromosomes
CN103352030B (zh) 含有减毒瘟病毒的疫苗
KR100939050B1 (ko) Bvdv 바이러스-유사 입자
Suter et al. Immunogenic and replicative properties of classical swine fever virus replicon particles modified to induce IFN-α/β and carry foreign genes
CA2663142C (en) Pestivirus mutant for use in a vaccine
AU2005279303B2 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
EP3498850B1 (en) Heterologous expression cassette, dna construct and vaccine composition for immunizing against flavivirus and/or other pathogens
AU3757199A (en) Chimeras of hepatitis c virus and bovine viral diarrhea virus
US20170128563A1 (en) Live Attenuated Classical Swine Fever Vaccine Based in Genetic Manipulation of a Putative Fusion Peptide Area in the Virus Structural Glycoprotein E2
EP1650308A1 (en) Nucleic acid sequences encoding proteins capable of associating into a virus-like particle
Arch Heinz et al.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140528

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150413

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150609

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150713

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150901